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Heparan-sulfate proteoglycans (HSPGs) are required for maximal growth factor signaling in prostate cancer progression. The
degree of sulfate modiﬁcation on the covalently attached heparan sulfate (HS) chains is one of the determining factors of growth
factor-HSPG interactions. Sulfate groups are transferred to HS chains via a series of O-sulfotransferases. In the present study,
we demonstrate that Heparan sulfate 2-O-sulfotransferase (2OST) is essential for maximal proliferation and invasion of prostate
cancercellsintheLNCaP-C4-2Bmodel.Wealsoshowthatadecreaseininvasiondueto2OSTsiRNAisassociatedwithanincrease
in actin and E-cadherin accumulation at the cell surface. 2OST expression correlates with increasing metastatic potential in this
model. We demonstrate that 2OST expression is upregulated by the stress-inducible transcription factors HIF1α,A T F 2 ,a n dN F κB.
Chromatin immunoprecipitation analysis suggests that HIF1α and ATF2 act directly on the 2OST promoter, while NFκBa c t s
indirectly.
1.Introduction
Heparan sulfate proteoglycans (HSPGs) are ubiquitous cell
surface molecules that consist of a protein core with attached
heparan sulfate (HS) glycosaminoglycan chains. HSPGs are
extremely important in both development and cancer pro-
gression due to their regulation of cellular processes such as
angiogenesis, tumor growth, proliferation, tumor invasion
and metastasis. HSPGs control various processes by modu-
lating a variety of growth factor signaling pathways such as
Sonic Hedgehog (SHH), FGF, VEGF, and TGFβ [1–3]. These
signaling pathways are abnormally activated in many cancers
including prostate cancer [4, 5].
HSPGs such as Syndecan-1 and Perlecan (Pln) are in-
volved in the regulation of tumor growth and proliferation
of prostate cancer cells [6–9]. Our group, along with collab-
orators, demonstrated the association of high levels of Pln
protein with 54% of advanced prostate cancer tumors and its
role in tumor cell proliferation by regulating SHH signaling
[8]. This led to the hypothesis that a subset of prostate
cancers reach advanced stage by increasing growth factor
signaling through increasing the amount of Pln coreceptor
in the extracellular matrix. However, the other 46% of
advanced prostate cancers showed no increase in Pln protein
levels compared to more benign tissue, suggesting another
mechanism is in play. Interestingly, in the LNCaP-C4-2B
cell line series, a well-known model of prostate cancer
progression [10–12], we have shown that SHH signaling
increaseswithincreasingmetastaticpotentialbutPlnprotein
levels do not [8]. Instead, in this cell line series, Pln isolated
from more highly metastatic cell lines binds more SHH than
an equal amount of Pln from more benign cell lines. This
data suggested an alternative mechanism, whereby during
prostate cancer progression, cells produce a diﬀerent, more
eﬃcient isoform of Pln protein to increase SHH signaling
rather than simply expressing more of the same isoform
as before. Given the bipartite structure of HSPGs and the
known contribution of their sugar chains to the regulation
of growth factor signaling, diﬀerential structure of the sugar
chains is an obvious possibility in the generation of diﬀerent
Pln isoforms.
The ability of HS to bind growth factors such as FGF,
VEGF, and hepatocyte growth factor has been shown to
largely depend on the amount of HS sulfation [13–16]. The2 Prostate Cancer
general rule is that the higher degree of sulfation on the HS
chain the greater the binding to growth factors. One possible
way of increasing the amount of sulfation on HS chains is
for the cell to increase the expression of the diﬀerent O-
sulfotransferases (OSTs) that act upon the glycosaminogly-
can chain [17]. We have chosen to investigate the impact of
cellular stress, a common characteristic of tumor progres-
sion, on the expression of these enzymes and the eﬀect of
changes in enzyme expression on cancer cell behavior.
Solid tumors, such as prostate cancer, make up approxi-
mately 90% of all cancers and result in signiﬁcant mortality
due to cell invasion and metastasis to distant vital organs
such as the brain and lungs [18]. The rapid proliferation
associated with formation of a solid tumor induces stress in
the tumor, such as hypoxia. Cells respond to hypoxic stress
by stabilizing the transcription factor hypoxia-inducible
factor 1α (HIF1α) which heterodimerizes with HIF1β and
activates transcription of its target genes [19]. HIF1α is
also stabilized in response to metabolic stress produced
by mitochondrial mutations that increase production of
reactive oxygen species (ROS) [20]. Finally, HIF1α activity
is increased in response to androgen signaling in androgen-
sensitive prostate cancer cells [21]. The HIF1 heterodimer
binds to speciﬁc sites called hypoxia response elements
(HREs) within the promoter of a target gene. HIF1α is a
logical candidate to control OST expression, because it is
overexpressed in prostate tumors [22]a sw e l la si nh u m a n
prostate cancer cell lines [23]. The accumulation of reactive
oxygen species (ROS) is another source of cellular stress
shown to be associated with solid tumors [24]. ROS activates
a number of stress-activated protein kinases. These kinases
activate transcription factors that stimulate the expression of
genes involved in cancer progression. We have focused on
two ROS-inducible transcription factors, NFκBa n dA T F 2 ,a s
well as the protein kinase p38 MAPK.
WequeriedtheOncominedatabaseandfoundthat2OST
expression is upregulated in prostate carcinoma compared
to normal tissue in three previously published reports
(Varambally, Luo, and Liu). This evidence led us to further
investigate the role of 2OST in prostate cancer and its pro-
gression. We have found evidence that the level of expression
of the 2OST enzyme correlates with metastatic potential in
the LNCaP-C4-2B cell line model. We also demonstrate that
the proliferation of these cells as well as their migration
is dramatically reduced when 2OST expression is knocked
down. Decreased migration of C4-2B cells through matrigel
as a result of 2OST knockdown correlates with increases in
cell adhesion via E-cadherin accumulation. We also demon-
strate that 2OST is required for optimal FGF, TGFβ,a n d
SHH signaling in C4-2B. Complex formation between the
SHHandtheHSPGPln,aninteractionknowntoberequired
for optimal signaling, is also decreased upon inhibition
of 2OST expression. Finally, we show that maximal 2OST
expression requires the stress-inducible transcription factors
HIF1α,A T F 2 ,a n dN F κB. Chromatin immunoprecipitation
studiessuggestthatHIF1αandATF2actdirectlyonthe2OST
promoter while NFκB acts indirectly. Taken together, our
studies strongly suggest that increases in 2OST levels, and
presumably modiﬁcation of HS chains on heparan sulfate
proteoglycans, account for the increased metastatic behavior
of a well-characterized model of prostate cancer progression.
Furthermore, these studies are consistent with the possibility
that the 46% of advanced human prostate cancer tumors
that failed to show an increase in Perlecan protein levels
over normal tissue may have progressed to a metastatic
state through production of a more eﬃcient form of highly
sulfated Perlecan due to upregulation of 2OST expression.
2.MaterialsandMethods
2.1. Cell Lines and Culture Conditions. The LNCaP series
(LNCaP, C4, C4-2, C4-2B) were obtained from Dr. L. Chung
and grown at 37◦C and 5% CO2 in T-medium supplemented
with 5% fetal bovine serum (Invitrogen).
2.2. Reagents and Antibodies. Primary antibodies purchased
from Santa Cruz Biotechnology (SCBT) are as follows: anti-
HS2ST1 (Santa Cruz no. sc-130779), anti-β-catenin (sc-
7963, 1:500), anti-phospho-ERK (sc-81492, 1:1000), anti-
phospho-SMAD2/3(sc-11769,1:1000),anti-phospho-ATF2
(sc-52941, 1:500), and anti-SHH (sc-9024, 1:500). Anti-
E-cadherin was purchased from Invitrogen (no.18-0223).
Anti-Pln antibody was purchased from US Biological (no.
H1890, 1:1000) and anti-HIF1α antibody was purchased
from Novus (NB100, 1:500). Puriﬁed anti-β-actin antibody
(A5316, 1:1000) was purchased from Sigma Aldrich. Anti-
mouse HRP and antirabbit HRP secondary antibodies
(1:10,000) were purchased from Jackson Labs. Antibodies
for chromatin immunoprecipitation were used at a ﬁnal
concentration of 0.3mg/mL and as follows: anti-HIF1α
(Novus Biologicals no. NB100), anti-ATF2 (SCBT sc-6233),
and anti-NFκB p65 (SCBT sc-109). SB202190 (Cat. no.
S7067) was purchased from Sigma Aldrich.
2.3. Western Blotting and Coimmunoprecipitations. Isolation
of total protein was done using the Mammalian Cell Lysis
Kit from Sigma Aldrich (no. MCL-1KT) according to
manufacturer’s protocol. Phosphatase inhibitors were used
for each sample (Sigma Aldrich no. P0044). Samples were
prepared and run on 15% SDS-PAGE and transferred onto
nitrocellulose. Western blots were developed with Pierce
ECL Western Blotting Substrate (no. 32106). Images and
densitometry were obtained on a BioRad ChemiDoc XRS
machine using Quantity One software. Densitometry values
represent the mean of two independent experiments. Pln-
SHH coimmunoprecipitations were performed as previously
described [8]. Brieﬂy, conditioned medium from C4-2B
cells treated with either control siRNA or 2OST siRNA was
collectedwhencellsreached80%–90%conﬂuencein100×15
culture dishes. Equivalent amounts of conditioned medium
were immunoprecipitated with anti-Pln antibody and the
bound complexes were run on SDS-PAGE. Bound SHH was
observed by immunoblotting.
2.4.TransientTransfections. TransienttransfectionsofsiRNA
were performed using Lipofectamine 2000 reagent (Invit-
rogen no. 11668027) for siRNA directed towards HIF1α,Prostate Cancer 3
NFκB, or ATF2 (Ambion) according to manufacturer’s
protocol. 2OST siRNA (Sigma no. SASI Hs01 00214049 and
SASI Hs01 00214052) was performed using Oligofectamine
transfection reagent (Invitrogen no. 12252011) according to
manufacturer’s protocol. Brieﬂy cells were cultured in 6-well
plates at allowed to attach for 24 hours. siRNA was applied
and cells were harvested for either protein or RNA after 24
hours. Scrambled siRNA was used as the negative control.
Transient transfection of stabilized HIF1α (stHIF1α) (a kind
gift from Dr. Eric Huang) as well as p2OST-lacZ reporter
plasmid were performed using Lipofectamine 2000 reagent
according to manufacturer’s protocol.
2.5. RNA Isolation and Real-Time PCR. Cells were grown
to 80%–90% conﬂuence, scraped, centrifuged and washed
withPBS.RNAisolationwasperformedwithQiagenRNEasy
Mini-kit (no. 74104) according to manufacturer’s protocol.
2μg of RNA was used in each DNAse I reaction using
DNAse I Ampliﬁcation Grade from Invitrogen (no. 18068).
Reverse transcription was performed with oligo dT and
random hexamer primers using SuperScript III reverse
transcriptase from Invitrogen (no. 18080044). Real-time
PCR was performed using Taqman Gene Expression Assays
with Taqman Universal PCR Master Mix from Applied
Biosystems (no. 4324018). Each sample from two indepen-
dent experiments was run in triplicate at three diﬀerent
concentrations and normalized to levels of 18S rRNA. Fold
increase/decrease comparisons were calculated using the
delta-delta CT method. Data for each sample is presented
as the mean fold change compared to control and error is
presented as standard deviation. Reactions were performed
using a BioRad C1000 Thermal Cycler machine.
2.6. Proliferation Assay. BrdU (Sigma-Aldrich) was added to
the cells at a ﬁnal concentration of 20μMa n da l l o w e dt o
incubate for two hours. Immunocytochemistry on cell lines
with scrambled or 2OST siRNA was carried out with anti-
BrdU (Becton Dickinson) and HRP-conjugated secondary
antibodies (Boehringer Mannheim) using standard tech-
niques. Proliferation was quantiﬁed by counting the number
of BrdU-positive cells in a ﬁeld of 100 done in triplicate.
2.7. Migration Assay. Cell migration assays were performed
using Matrigel Invasion Chambers from BD Biocoat (no.
354480) and control inserts (no. 354578) according to
manufacturer’s protocol. Number of C4-2B cells migrated
through Matrigel was counted in control cells (scrambled
siRNA treated) and experimental cells (2OST siRNA treated)
in four separate ﬁelds in three independent experiments.
The same experiment was performed in control inserts. The
average number of invading cells through Matrigel (n = 12)
was normalized to the average number of cells on control
inserts (n = 12) to determine percent invasion. Error bars
indicate standard deviation.
2.8. Phalloidin Staining and E-cadherin-Phalloidin Double
Labeling. C4-2B cells were treated with scrambled siRNA
or 2OST siRNA as described above and cultured on glass
coverslips coated in poly-L-lysine (BD Biocoat no. 354085).
Cells were washed with PBS, ﬁxed in 3% formaldehyde, per-
meabilizedwithPBST,treatedwith1:1000dilutionofFITC-
phalloidin (Dr. B. Perkins), and mounted in VectaShield
mounting medium with DAPI (Vector Laboratories). Cells
were imaged with ﬂuorescence microscopy. Individual cells
were ﬁrst chosen by their nuclei under the DAPI channel,
then the number of actin foci per cell were counted for
each treatment (n = 15 per treatment). The double labeling
experiment was performed in much the same way as
the phalloidin staining of C4-2B cells treated with either
control or 2OST siRNA with a few modiﬁcations. Following
permeabilization with PBST ﬁxed cells were blocked with
0.1% FBS in PBS. α-E-cadherin antibody was added to a
ﬁnal concentration of 0.5μg/mL for 30 minutes then cells
were washed with PBS three times. A 1:1000 dilution of
α-mouse Alexa 488 secondary antibody was added for 30
minutes then followed with three more rounds of washing.
Cells were then treated with a 1:40 dilution of Alexa 546
phalloidin for 20 minutes then washed again. Cells were
air dried and mounted on microscope slides in Vectashield
mounting medium with DAPI.
2.9.p2OSTReporterPlasmidandβ-galactosidaseAssays. Two
diﬀerent constructs from the 2OST promoter were ampliﬁed
by PCR and cloned into the pBLUE-TOPO TA vector
(Invitrogen no. K4831-01). “Full-length” p2OST consists
of 2500 bases upstream and 435 bases downstream of
the transcription start site while “4C” p2OST consists
of 1500 bases upstream and 435 bases downstream of
the transcription start site. Primers used to amplify the
“full-length” promoter were 5 -tcaaacggtgaaccaagacgctgt-3 
and 5 -gaaacccgctgctcggg-3 . Primers used to amplify the
“ 4 C ”p r o m o t e rw e r e :5  -actccggtgtagtcccttaaca-3  and 5 -
gaaacccgctgctcggg-3 . β-galactosidase assays to evaluate the
amount of transcription from each of the p2OST constructs
were performed using the β-gal Assay Kit (Invitrogen no.
K1455-01) according to manufacturer’s protocol.
2.10. Chromatin Immunoprecipitation. C4-2B cells were
cross-linked by adding formaldehyde directly to cell culture
medium to a ﬁnal concentration of 1%. Cross-linking was
allowed to proceed for 10min at room temperature then
stopped with addition of glycine to a ﬁnal concentration
of 0.125M. Cells were washed twice with ice-cold PBS and
swollen with PBS for 10 minutes at 37◦C. Cells were scraped,
washedoncewithPBSthenpelletedbycentrifugation.Pellets
were resuspended in Cell Lysis Buﬀer (5mM PIPES pH 8.0,
85mM KCl, 0.5% Triton X-100, protease inhibitor cocktail)
for 10 minutes on ice. Cellular extract was pelleted by
centrifugation then nuclei were resuspended in Nuclei Lysis
Buﬀer (50mM Tris-Cl pH 8.0, 10mM EDTA, 1% SDS,
protease inhibitor cocktail) for 10 minutes on ice. Total
chromatin was then sonicated for twelve 20-second pulses
at setting 2. After centrifugation at 12,000g chromatin was
precleared with Protein A/G Plus Beads then divided into
aliquots. Antibody was added to each aliquot for a ﬁnal
concentration of 0.3mg/mL and incubated on a rotating4 Prostate Cancer
platform overnight at 4◦C. Antibody-protein complexes
were immunoprecipitated with Protein A/G Plus Beads.
Samples were washed extensively and eluted in Elution
Buﬀer (50mM NaHCO3, 1% SDS). Bound DNA fragments
were isolated and analyzed by PCR. Primers used to
amplify the region of the 2OST promoter from −1157 to
−707 (H1) were 5 -ttaaaagcacaaatcgcactca-3  and 5 -gaa-
aagggtggggaggact-3 . Primers used to amplify the region
from−581to−231(H2andA2)were5 -ggcaccagacacccactc-
3  and 5 -aagaaggcggggctaaaac-3 . Primers used to amplify
the region from −1499 to −1219 (A1) were 5 -actccg-
gtgtagtcccttaaca-3  and 5 -tttttaaatgatgttcgttgtcttc-3 .P r i m -
ers used to amplify the region from +224 to +435 (N1) were
5 -gactggagaggcgagaagg-3  and 5 -gaaacccgctgctcggg-3 .P r i -
mersusedtoamplifytheregionfrom −176to+53(N2)were:
5 -caaccgtaaaccgaaccaag-3  and 5 -tccctctcttccttccttcc-3 .
2.11. Promoter Analysis. Prediction of transcription factor
binding sites in the human 2OST promoter was done with
the ALGGEN-PROMO prediction program.
3. Results
3.1. OST Expression Is Upregulated in Prostate Carcinoma. To
investigate the role of 2OST in prostate cancer, we explored
the Oncomine database (https://www.oncomine.org/). The
Oncomineconceptthatwaschosenwas“ProstateCarcinoma
versus Normal—Top 10% overexpressed.” Within this con-
cept we found three diﬀerent studies that included 2OST in
the cDNA microarray. Each of these studies show that 2OST
expression is signiﬁcantly upregulated in prostate carcinoma
compared to normal tissue (Table 1). This evidence led us to
furtherexaminetheroleof2OSTinprostatecancerusingthe
LNCaP-C4-2B model of prostate cancer progression.
3.2. 2OST Expression Correlates with Metastatic Potential.
The LNCaP-C4-2B cell line model of prostate cancer pro-
gression was originally identiﬁed in the laboratory of Dr.
Leland Chung [11, 12]. This series of lines was established
via serial transplantation of cancer cells into nude mice. The
LNCaP cell line was originally derived from a supraclavicular
lymph-node metastasis of a primary prostatic carcinoma
[25]. LNCaP cells mimic many of the characteristics of early
stage prostate cancer in that they are weakly tumorigenic
when inoculated into nude mice, their growth is androgen-
sensitive and they secrete low levels of PSA [25]. The C4
subline shows higher levels of PSA expression than LNCaP,
produces approximately 10 times more colonies in soft agar
and are still androgen-sensitive in their growth. The next
subline in the series, C4-2, is highly tumorigenic on its own,
displays androgen insensitive growth and metastasizes to
both the lymph node and bone. The ﬁnal subline of the
series, C4-2B, mimics the most advanced stage of prostate
cancer. It is androgen-insensitive, secretes the highest levels
of PSA, and rapidly metastasizes to bone.
To ask if 2OST might play a role in the invasive and
metastatic potential of cell lines in the LNCaP-C4-2B series
we ﬁrst evaluated basal expression of the 2OST gene in
Table 1: 2OST is overexpressed in prostate carcinoma compared to
normal tissue. The Oncomine concept “Prostate Carcinoma versus
Normal—Top 10% Overexpressed” was queried in Oncomine
(https://www.oncomine.org/). 2OST (HS2ST1) was signiﬁcantly
overexpressed in three diﬀerent expression studies.
Prostate Carcinoma versus Normal—Top 10% Overexpressed
Study Fold change P value
Varambally prostate 3.43 0.015
Luo prostate 2 1.8 0.003
Liu prostate 1.413 0.002
each of the cell lines. Quantitative real-time PCR analysis
of 2OST mRNA levels using the weakly tumorigenic LNCaP
line as a normalization standard reveals a step-wise increase
in 2OST expression as the cell lines increase in their
metastatic potential (Figure 1). Levels of 2OST increased
fourfold in the C4-2B cell line as compared to LNCaP. This
result demonstrates a direct correlation between increasing
characteristics of advanced prostate cancer cells and 2OST
expression.
3.3. Knockdown of 2OST Expression Results in Decreased
Prostate Cancer Cell Proliferation and Migration. The cor-
relation between 2OST expression and metastatic potential
suggested that 2OST might play a role in metastasis-
associated processes of the LNCaP-C4-2B cell line series.
To investigate this possibility, we asked if changes in the
level of 2OST would aﬀect cellular proliferation. We assayed
cell proliferation using BrdU incorporation in each cell line
eithertransfectedwithacontrolsiRNA(blackbars)orsiRNA
directed against 2OST (white bars) (Figure 2(a)). We found
that proliferation decreased in each of the four cell lines as
a result of the 2OST siRNA. The proliferation of the most
advanced cell lines was the most sensitive to knockdown of
2OSTexpression.Toverifyadecreaseintheamountof2OST
protein as a result of the siRNA treatment, Western blot
analysis was performed on C4-2B cells treated with either the
control siRNA or 2OST siRNA. We were able to reproducibly
detect an approximate decrease of 50% in levels of 2OST
protein (Figure 2(b)). In summary, the 2OST enzyme is
necessary for optimal proliferation of prostate cancer cells in
the LNCaP-C4-2B cell line series.
Along with proliferation, cell invasion is one of the
principal processes that are required for cancer progression
and metastasis. The correlation we observed between 2OST
expression and metastatic potential suggested that a decrease
in 2OST expression would lead to a decrease in the invasive
potential of thesecells.To determine if inhibition of 2OSTby
siRNA aﬀects prostate cancer cell invasion, we evaluated the
invasive potential of the most metastatic cell line C4-2B in
an in vitro Matrigel invasion assay. C4-2B was chosen for this
experiment due to its proliferation being the most sensitive
to 2OST siRNA and it having the highest levels of 2OST
expression. Approximately 80% of C4-2B cells treated with
control siRNA invaded through Matrigel demonstrating its
high invasive potential (Figure 2(c)). Inhibition of 2OST by
siRNA in C4-2B cells resulted in a signiﬁcant decrease in theProstate Cancer 5
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Figure 1: 2OST expression correlates with metastatic potential. A 2OST mRNA levels in LNCaP series of prostate cancer progression. 2OST
mRNA was assayed by qRT-PCR and normalized to 18S rRNA. All samples were run in triplicate and overall 2OST message levels compared
bysetting2OSTlevelsinLNCaPto1.Samplesarepresentedbyincreasingmetastaticpotential(LNCaP,C4,C4-2,C4-2B).Errorbarsindicate
standard deviation. Asterisk indicates P<0.05.
meannumberofcellsthatinvadedthroughtheMatrigel(P<
0.01). Percent invasion of 2OST siRNA treated cells dropped
to approximately 50% (Figure 2(c)). Figure 2(d) shows a
representative ﬁeld of C4-2B cells treated with either control
siRNA(a,c)orthe2OSTsiRNA(b,d).Thisdatademonstrates
that optimal in vitro migration of highly metastatic prostate
c a n c e rc e l l sr e q u i r e s2 O S T .
3.4. Increased Actin and E-cadherin Accumulation in C4-2B
Cells Treated with 2OST siRNA. Cell adhesion in epithelial
c e l l si sp r o v i d e di np a r tb yt h ef o r m a t i o no fa d h e r e n s
junctions. These cell to cell contacts consist of the proteins
E-cadherin, β-catenin, α-catenin, and actin ﬁlaments [26].
Adherens junctions are formed between epithelial cells, such
as those in the prostatic duct, when plasma-membrane
spanning E-cadherin proteins recruit catenin molecules,
which in turn bind to actin ﬁlaments. The junctions are
stabilized by the formation of E-cadherin clusters and then
further stabilized by the accumulation of actin ﬁlaments
at the contact region [27, 28]. During the progression of
metastatic disease, epithelial cells lose cell-cell contacts via
adherens junctions and become ﬁbroblast like in a process
called the epithelial-mesenchymal transformation (EMT)
[27]. Due to the decreased invasion of C4-2B cells that
have been treated with 2OST siRNA, we hypothesized that
2OST acts to repress adherens junction formation. To test
this hypothesis, we evaluated the accumulation of actin via
phalloidin staining in C4-2B cells treated either with control
siRNA or 2OST siRNA (Figures 3(a)-3(b)). A signiﬁcant
increase in the mean number of actin foci per cell in C4-2B
cells treated with 2OST siRNA was observed (Figure 3(b)).
Figure 3(a) shows representative cells of each treatment.
Notice the accumulation of phalloidin staining in the 2OST
siRNA treated cell.
To determine if these actin foci might correspond to
the formation of adherens junctions, we evaluated actin-E-
cadherin double labeling in C4-2B cells treated with either
control siRNA or 2OST siRNA (Figure 3(c)). Control siRNA
treated cells had very low levels of both actin and E-cadherin
accumulation (a,b). 2OST siRNA treated cells once again
had accumulation of actin as shown by phalloidin staining
(bottom row, third panel from left). These cells also had
signiﬁcantly increased levels of E-cadherin accumulation
at the membrane, especially in the same regions that had
increased actin accumulation (bottom panels, second and
fourth panes from left). These results suggest that the
inhibition of 2OST by siRNA is facilitating the formation of
adherens junctions and thus a possible reversal of EMT.
The possibility exists that the loss of 2OST is allowing
for an increase in E-cadherin expression that in turn permits
formation of these junctions. To test this possibility, we
performedWesternblotanalysisofE-cadherinproteininC4-
2B cells treated with either control siRNA or 2OST siRNA
(Figure 3(d)). No signiﬁcant increase in total cellular E-
cadherin protein was observed in cells treated with 2OST
siRNA. This result suggests that the localization of available
E-cadherin in C4-2B cells changes from a more diﬀuse
pattern to accumulation of foci when treated with 2OST
siRNA.
3.5. Inhibition by 2OST siRNA Results in Decreased Growth
Factor Signaling and Complex Formation between Perlecan
and SHH in Prostate Cancer Cells. To ask if 2OST modulates
growth factor signaling in C4-2B cells, we used commonly
used assays to determine levels of FGF, TGFβ, Wnt, and
Sonic Hedgehog (SHH) signaling in cells transfected with
2OST siRNA. To determine the eﬀect of 2OST siRNA on
FGFsignaling,Westernblotswereperformedanalyzinglevels
of phospho-ERK. Densitometry reveals that phospho-ERK
levels were decreased 50% in C4-2B as a result of 2OST
inhibition by siRNA when using actin as normalization
controls (Figure 4(a)). We then assayed the eﬀect of 2OST
knockdown on TGFβ signaling by performing western blots
for phospho-SMAD2 while using total SMAD2 as a normal-
ization control. Densitometry analysis reveals that levels of
phospho-SMAD were decreased approximately 35% in C4-
2B transfected with 2OST siRNA (Figure 4(b)). We assayed
levels of β-catenin as readout of the eﬀect of 2OST siRNA
on Wnt signaling. Levels of β-catenin were only decreased
approximately 15% in C4-2B transfected with 2OST siRNA6 Prostate Cancer
0
20
40
60
80
100
120
LNCaP C4 C4-2 C4-2B
B
r
d
U
i
n
c
o
r
p
o
r
a
t
i
o
n
(
%
)
∗ ∗ ∗
∗
(a)
C
o
n
t
r
o
l
2
O
S
T
R
N
A
i
2OST
Actin
1 0.32
(b)
0
10
20
30
40
50
60
70
80
90
100
R
e
l
a
t
i
v
e
m
i
g
r
a
t
i
o
n
n
o
r
m
a
l
i
z
e
d
t
o
c
o
n
t
r
o
l
∗
Control 2OST RNAi
(c)
2OST RNAi
M
a
t
r
i
g
e
l
C
o
n
t
r
o
l
RNAi Control
(d)
Figure 2: Inhibition by 2OST siRNA decreases prostate cancer cell proliferation and migration. (a) BrdU incorporation in LNCaP, C4,
C4-2, and C4-2B cell lines. The cell lines are listed in order of increasing metastatic potential from left to right on the graph. All samples
were normalized to controls (scrambled siRNA treated). Black bars represent control samples transfected with scrambled siRNA. White bars
represent samples transfected with 2OST siRNA. Error bars represent n = 3 independent samples and standard deviation. Asterisk indicates
P<0.05. (b) Western blot for veriﬁcation of 2OST siRNA. Levels of 2OST in each sample were normalized to actin by densitometry. Values
are representative of two independent experiments. (c) Inhibition by 2OST siRNA decreases Matrigel invasion by C4-2B cells. The number
of C4-2B cells that migrated through Matrigel was counted for control cells (scrambled siRNA treated) and experimental cells (2OST siRNA
treated) in four separate ﬁelds in three independent experiments. The same experiment was performed with control inserts. The average
number of invading cells (n = 12) was normalized to the average number of cells on control inserts (n = 12) to determine percent invasion.
Average % invasion for control and 2OST siRNA cells were 81.8 ± 6.88 and 49.8 ± 4.08, respectively (P<0.01, asterisk). (d) Representative
images of C4-2B cells used in Matrigel assay. Cells that migrated through the matrigel in either control or 2OST siRNA samples are shown
in (a,b). Cells used in control inserts are shown on (c,d).
compared to controls (Figure 4(c)). In summary, we propose
that inhibition of 2OST siRNA has signiﬁcant eﬀects on FGF
and TGFβ signaling but not on Wnt signaling.
Finally, to determine the eﬀect of 2OST siRNA on
SHH signaling, we performed qRT-PCR on RNA isolated
from C4-2B cells treated with either control siRNA (black
b a r s )o r2 O S Ts i R N A( w h i t eb a r s )a n de v a l u a t e dl e v e l s
of the response genes PTCH and GLI1 (Figure 4(d)). We
demonstrate that PTCH levels decrease approximately 40%
and GLI1 levels decrease approximately 70% as a result of
2OST knockdown. Our group has previously shown that
SHH binds more readily to Pln secreted from the highlyProstate Cancer 7
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Figure 3: Inhibition by 2OST siRNA increases actin foci in C4-2B cells. (a) Fluorescence staining for F-actin (left panels) and nuclei (right
panels) in C4-2B cells treated with 2OST siRNA (bottom row) or control siRNA (top row). Notice the clustering of F-actin into foci in the
2OST siRNA treated cells. (b) Quantitation of number of actin foci present per cell in C4-2B cells treated with scrambled siRNA (control,
black bar) and 2OST siRNA (white bar). Mean number of foci per cell ± sem are 0.33 ± 0.03 and 1.14 ± 0.06 respectively (n = 15). Asterisk
indicates P<0.05. (c) Inhibition by 2OST siRNA increases E-cadherin staining that colocalizes with actin foci in C4-2B cells. Fluorescence
immunohistochemistry for DAPI stained nuclei (left column); E-cadherin (second column), F-actin (third column), and merged images
(fourth column) in C4-2B cells treated with 2OST siRNA (bottom row) or scrambled siRNA (top row). Notice accumulation of E-cadherin
between cells treated with 2OST siRNA. (d) Inhibition by 2OST siRNA does not result in signiﬁcant upregulation of E-cadherin protein.
Western blot of E-cadherin in samples treated with scrambled siRNA or 2OST siRNA. Levels of E-cadherin were normalized to actin. Values
represent two independent experiments.8 Prostate Cancer
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Figure 4: 2OST modulates growth factor signaling in cell line model of prostate cancer progression. (a) Decreased FGF signaling in cells
treatedwith2OSTsiRNA.Westernblottingforphospho-ERKandβ-actinperformedasdescribedinMaterialsandMethods.Levelsofp-ERK
are normalized to β-actin. Densitometry ﬁgures are shown below each sample and are representative of two independent experiments. (b)
Decreased TGFβ signaling in cells treated with 2OST siRNA. Levels of p-SMAD2 normalized to total SMAD2. (c) Decreased Wnt signaling
in cells treated with 2OST siRNA. Levels of β-catenin normalized to β-actin. (d) Decreased SHH signaling in cells treated with 2OST siRNA.
Real-time PCR analysis of SHH pathway response genes PTCH and GLI1 was performed. Error bars indicate standard deviation. Asterisk
indicates P<0.05. (e) Decreased complex formation between SHH and Pln. Pln was immunoprecipitated from conditioned media from
either control siRNA or 2OST siRNA cells. Left pane shows western blot for SHH bound to equal amounts of Pln. Right panel shows equal
amounts of SHH in input samples from coimmunoprecipitation.
metastatic C4-2B as compared to Pln secreted from the
weakly tumorigenic LNCaP cell line [8]. To determine if
the 2OST enzyme is required for optimal Pln-SHH complex
formation in C4-2B, we performed coimmunoprecipitations
in which Pln protein was pulled down from conditioned
medium of C4-2B cells treated with either control siRNA
or 2OST siRNA. Western blotting to determine the levels of
SHH bound to equivalent levels of Pln in each treatment
reveals a signiﬁcant decrease in Pln-SHH complex formation
in samples treated with 2OST siRNA as compared to control
siRNA (Figure 4(e)). Overall, our results suggest that the
2OST enzyme is needed for optimal growth factor signaling
in the highly metastatic prostate cancer cell line C4-2B.
3.6. HIF1α Stimulates Expression of 2OST by Directly Binding
Promoter in C4-2B. The cellular stress hypoxia has been
shown to correlate with increased tumor invasiveness and
metastatic potential [29]. Hypoxic stress increases the stabil-
ity of the transcription factor HIF1α, allowing it to activate
gene expression; however, even prostate cancer cell lines
grown under normoxic conditions have been demonstrated
to have high levels of HIF1α protein [30, 31]. This may be in
partduetothepotentialofreactiveoxygenspeciestostabilize
HIF1αaswellastheabilityofandrogensignalingtostimulate
HIF1α activity [21, 32]. To investigate whether the hypoxic
stress-induced transcription factor HIF1α activates 2OST
expression, we analyzed the sequence of the proximal 2OSTProstate Cancer 9
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Figure 5: HIF1α activates 2OST expression in model of prostate cancer progression. (a) Schematic of 2OST promoter with regions of
HREs (H1 and H2). (b) C4-2B cells were transfected with vector expressing stHIF1α. Real-time PCR for 2OST levels normalized to 18S
levels in each sample. Black bars represent control vector alone transfected samples and gray bars represent stHIF1α transfected samples.
Error bars indicate standard deviation. (c) Western blot for HIF1α shows increased accumulation of stabilized transcription factor in cells
transfected with stHIF1α vector. (d) Inhibition of endogenous HIF1α expression by siRNA results in decreased levels of 2OST mRNA. Real-
time PCR analysis of HIF1α and 2OST normalized to levels of 18S. Black bars represent samples treated with scrambled siRNA-treated
samples, white bars represent levels of either HIF1α or 2OST in HIF1α siRNA-treated cells. Error bars indicate standard deviation. Asterisk
indicates P<0.05. (e) HIF1α binds directly to the 2OST promoter at predicted HREs. Chromatin Immunoprecipitation analysis of C4-2B
total chromatin, HIF1α IP, no antibody (NoAB), and Mock samples. Samples were analyzed by PCR with primers ﬂanking each HRE site.
Positive control primers were used from the VEGF promoter [33].
promoter and found putative HRE sequences approximately
1000 bases (H1) and 500 bases (H2) upstream of the
transcriptionstartsite(Figure 5(a)).Wethenaskedifoverex-
pression of HIF1α would be able to activate transcription of
the 2OST gene. To answer this question, we evaluated levels
of 2OST mRNA via qRT-PCR in C4-2B cells transfected
with either an empty control vector (black bar) or a vector
expressingastabilizedformofHIF1α(graybar).Itwasfound
that 2OST levels increased approximately twofold in cells
overexpressing the stabilized HIF1α (Figure 5(b)). To verify
accumulation of HIF1α due to the overexpression vector,
Westernblotanalysiswasperformedandrevealssigniﬁcantly
increased levels of HIF1α as a result of the stabilized HIF1α
transgene (Figure 5(c)). To determine if siRNA-mediated
knockdown of endogenous HIF1α expression aﬀected levels
of 2OST mRNA, we analyzed levels of both HIF1α and 2OST
mRNA in samples transfected with HIF1α siRNA (white
bars) compared to control siRNA samples (black bars).
HIF1α levels were decreased 90%, while 2OST mRNA was
decreased 45% as a result of the HIF1α siRNA (Figure 5(d)).
These results suggest that the HIF1α transcription factor
activates expression of the 2OST gene in C4-2B prostate
cancer cells.
We then asked if the eﬀect of HIF1α on 2OST tran-
scription was direct or indirect. To answer, this chromatin
immunoprecipitation (ChIP) assays were performed to eval-
uate physical interactions between transcription factor and
promoter at the putative HREs. HIF1α has previously been10 Prostate Cancer
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Figure 6: Inhibition of p38 MAPK or ATF2 results in decrease in 2OST mRNA. (a) Schematic of 2OST promoter with regions of predicted
ATF2 binding sites (A1 and A2). (b) Real-time PCR analysis of 2OST levels in cells treated with either DMSO (control, black bars), 40μM
(gray bars), or 80uM SB202190 (speciﬁc p38 MAPK inhibitor, white bars) for 12 hours. Error bars indicate standard deviation. (c) 2OST
promoter β-galactosidase reporter assay in cells treated with either DMSO control (black bars) or 80μM SB202190 (gray bars). Full-length
2OST promoter represents region 2500 bases upstream to 500 bases downstream of transcription start site. 4C represents region 1500 bases
upstream to 500 bases downstream from start site. Error bars indicate standard deviation. (d) Western blot showing decreased levels of
phospho-ATF2 in cells treated with 80μM SB202190. (e) Inhibition of ATF2 by siRNA results in decreased levels of 2OST mRNA. Real-time
PCR analysis of ATF2 and 2OST normalized to levels of 18S. Black bars represent samples treated with scrambled siRNA, gray bars represent
either ATF2 or 2OST levels in ATF2 siRNA-treated cells. Error bars indicate standard deviation. Asterisk indicates P<0.05. (f) Chromatin
Immunoprecipitation analysis of C4-2B total chromatin, ATF2 IP, no antibody (NoAB), and Mock samples. Samples were analyzed by PCR
with primers ﬂanking each predicted ATF2 site. Positive control primers were used from the human insulin promoter [36].
shown to directly bind the VEGF promoter [33]. Primers for
the VEGF promoter ﬂanking HREs were used as a positive
control (PC) and PCR analysis of chromatin pulled down
with HIF1α IP demonstrated that HIF1α does indeed bind
this promoter in C4-2B. PCR analysis using primers ﬂanking
the H1 and H2 regions of the 2OST promoter showed that
HIF1α binds directly to the proximal H2 site but no physical
interaction was detected at the H1 site (Figure 5(e)). Overall
these results suggest that HIF1α activates 2OST transcription
by directly binding its promoter.
3.7. p38 MAPK Signaling and ATF2 Stimulate Transcription
of 2OST in C4-2B. Accumulation of ROS and the resulting
oxidative stress has been shown to activate p38 MAP kinaseProstate Cancer 11
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Figure 7: Inhibition of NFκB by siRNA results in decreased 2OST mRNA. (a) Schematic representation of 2OST promoter with regions of
predicted NFκB-binding sites (N1 and N2). (b) Inhibition of NFκB by siRNA results in decreased levels of 2OST mRNA. Real-time PCR
analysis of NFκB and 2OST normalized to levels of 18S. Black bars represent samples treated with scrambled siRNA treated samples and gray
barsrepresenteitherNFκBor2OSTlevelsinNFκBsiRNAtreatedcells.Errorbarsindicatestandarddeviation.Asteriskindicates P<0.05.(c)
NFκB does not bind directly to the 2OST promoter at predicted binding sites in C4-2B. Chromatin immunoprecipitation analysis of C4-2B
total chromatin, NFκB IP, no antibody (NoAB), and Mock samples. Samples were analyzed by PCR with primers ﬂanking each predicted
NFκB site. Positive control primers were used from the PPM1D promoter [37].
[34]. Activation of p38 MAPK is also important for the
malignant phenotype in prostate cancer cells, and this is
due in part to activation of the transcription factor ATF2 by
phosphorylation [35]. We asked if ATF2 could be a possible
transcriptional activator of 2OST expression. Our analysis
of the sequence of the 2OST promoter showed two possible
regions of ATF2 binding sites that have been labeled A1 and
A2 (Figure 6(a)). To determine if p38 MAPK signaling was
involved in 2OST transcriptional activation, we evaluated
levelsof2OSTmRNAbyqRT-PCRincellstreatedwitheither
DMSO control (black bar) or increasing concentrations of
the speciﬁc p38 inhibitor SB202190 for 12 hours. We found
that treatment with 40μM SB202190 (gray bar) resulted
in a 55% decrease in 2OST levels, while treatment with
80μM inhibitor (white bar) resulted in a 90% decrease
(Figures 4-3(b)). This dose-dependent eﬀect of p38 MAPK
inhibitor suggests that signaling from the ROS-inducible
protein kinase is important for optimal 2OST expression. To
verify this eﬀect, we produced two diﬀerent β-galactosidase
reporter constructs to assay for 2OST promoter activity.
The “full-length” promoter represents the region from 2500
bases upstream of the transcription start to 435 bases
downstream and the “4C” promoter represents the region
from 1500 bases upstream to 435 bases downstream. p2OST
promoter activity was assayed in C4-2B cells transfected
with one of the reporter constructs treated with either
DMSO control (black bars) or 80μM SB202190 for 12 hours
(gray bars) (Figure 6(c)). We found that treatment with the
p38 inhibitor resulted in a signiﬁcant decrease in promoter
activity with both constructs. In addition, upon comparison
of results from the “full-length” reporter and the “4C”
reporter it became evident that deletion of the 1000 bases
most 5  in our promoter construct leads to an increase
in 2OST reporter expression, suggesting the existence of a
previously unsuspected inhibitory sequence between −1500
and −2500.
We then asked if inhibition of p38 MAPK leads to a
decrease in active ATF2 transcription factor in C4-2B. To
answer this, Western blot analysis was performed evaluating
levels of phospho-ATF2 in cells treated with DMSO control
or 80μM SB202190 for 12 hours. We observed a signiﬁcant
decrease in phosphorylated ATF2 levels as a result of p38
inhibition (Figure 6(d)). To determine if ATF2 is acting to
stimulate 2OST expression, we assayed both ATF2 and 2OST
mRNA levels in cells treated with ATF2 siRNA (gray bars) or
the negative control siRNA (black bars) (Figure 6(e)). The
results demonstrate that while ATF2 levels were knocked
down 90% 2OST levels were decreased approximately 75%12 Prostate Cancer
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Figure 8: Alternative model for increased extracellular HS in prostate cancer progression.
by the siRNA treatment. This suggests that p38 MAPK
activates ATF2, which in turn stimulates 2OST expression in
the C4-2B cell line.
We then asked if the eﬀect of ATF2 was direct or indirect
by performing ChIP assays on the 2OST promoter. Primers
ﬂanking ATF2 binding sites in the insulin promoter were
used as a positive control (PC) [36]. PCR analysis with
primers ﬂanking the putative ATF2 binding sites in the 2OST
promoter demonstrates a physical interaction between ATF2
and the promoter at the A2 site (Figure 6(f)). This result
suggests that the eﬀect of ATF2 on 2OST expression is direct
by binding of the proximal A2 site.
3.8. NFκB Indirectly Activates 2OST Expression in C4-2B.
The ROS-inducible transcription factor NFκB is another
candidate transcription factor to induce 2OST expression.
Analysis of the 2OST promoter reveals two regions that
contained putative NFκB binding sites (Figure 7(a),N 1
and N2). To determine if knockdown of NFκB expression
by siRNA results in a decrease in 2OST expression, we
assayed NFκB and 2OST mRNA levels in cells treated with
NFκB siRNA (gray bars) or control siRNA (black bars)
(Figure 7(b)). NFκB levels were successfully knocked down
∼80% by the siRNA treatment while 2OST levels also
decreased ∼80%. These results indicate that NFκB induces
2OST expression in C4-2B prostate cancer cells.
To determine if NFκB binds directly to the 2OST pro-
moter, we performed ChIP to assay for physical interaction
at the promoter (Figure 7(c)). Primers from the PPM1D
promoter were used as a positive control (PC) for direct
NFκB binding [37]. PCR analysis with primers ﬂanking
either the N1 or N2 regions of 2OST promoter demonstrated
that NFκB does not bind directly to either putative binding
site. These results indicate that the eﬀect of NFκBo n2 O S T
transcription is indirect in C4-2B.
4. Discussion
Studies analyzing the complete loss of HS in regards to
organismal and molecular phenotypes show that HS is
very important for biological processes in development and
disease. In an attempt to look more closely at HS ﬁne
structure, Merry et al. described the molecular phenotypes
o f2 O S T - n u l lm i c e[ 38]. They observed renal agenesis as well
as eye and skeletal defects. Recently, it was found that 2OST
is essential for FGF signaling required in chick limb bud
outgrowth and development [39].
We have chosen to analyze the eﬀect of changes in
HS ﬁne structure via 2OST siRNA on prostate cancer cell
proliferation and invasion to ask how changes in heparan
sulfation may arise during cancer progression (Figure 8).
Our studies have demonstrated that 2OST is required for
maximal proliferation and invasion of cells in the LNCaP-
C4-2B model. We also show that a knockdown of 2OST
expression coincides with an increase in actin and E-
cadherin accumulation at the cell surface, both markers
of adherens junction formation. Our results suggest that
2OST is upregulated at the transcriptional level as cells
increase in metastatic potential. We hypothesized that stress
conditions such as hypoxia and ROS production, known to
accompany cancer progression, and the cellular response to
these stresses contribute to increased 2OST expression. We
show that the stress-inducible transcription factors HIF1α,
ATF2 and NFκB are required for maximal 2OST expression.
Our results demonstrate that the ROS-inducible protein
kinasep38MAPKisalsorequired.Weproposethatincreased
2OST expression allows for increased sulfation of HS chains
on HSPGs, which allows for increased growth factor-HSPG
binding. Our group previously demonstrated that binding
of the SHH growth factor to Perlecan is upregulated in
highly metastatic cells. In this study, we show that 2OST is
required for this interaction in C4-2B cells. As a result ofProstate Cancer 13
increased growth factor-HSPG binding, we propose that HS-
d e p e n d e n tg r o w t hf a c t o rp a t h w a y sr e q u i r e2 O S T .W es h o w
that the SHH, FGF, and TGFβ pathways all require 2OST for
optimal signaling in highly metastatic C4-2B cells.
Previous studies from our group indicated that 54% of
malignant human prostate tumors displayed increased levels
ofPerlecan,whichcontributedtoincreasedproliferationand
SHH signaling [8]. In the current study, we characterize a
cell line model of prostate cancer progression that shows no
increase in Perlecan expression in an attempt to model the
46% of tumors that display basal levels of Perlecan. We intro-
duce a plausible alternative mechanism to achieve metastasis
through upregulation of 2OST. Another possibility would be
to increase the expression of other HSPGs such as Glypican
and Syndecan. To date no correlation between Glypican and
prostate cancer progression has been published. Two recent
studies suggest that Syndecan-1 correlates with increasing
metastatic potential in prostate cancer patients [6, 40].
Syndecan-1 may also be a target of 2OST function, thereby
contributing to prostate cancer progression.
2OST is unique among the HS sulfation enzymes in
humans due to its encoding by a single gene rather than a
gene family. This relative simplicity will facilitate its use as
both a marker and predictor of prostate cancer progression
in human biopsies. Furthermore, the fact that knockdown
of 2OST expression in the most malignant cell line, C4-2B,
caused those cells to become dramatically less invasive and
proliferative make 2OST an intriguing target of therapeutic
potential.
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